Date: 2014-12-02
Type of information: Licensing agreement
Compound: two hepatocellular carcinoma (HCC) molecular signatures
Company: Integragen (France) Inserm Transfert (France) Paris Descartes University (France)
Therapeutic area: Cancer - Oncology
Type agreement: licensing
Action mechanism: One signature is a subset of 16 genes which can be used to classify patients with hepatocellular carcinoma(HCC) into six distinct molecular groups with the ability to study the therapeutic response to treatment within these different groups. The second signature consists of 5 genes and is predictive of the clinical prognosis of patients diagnosed with HCC and treated by surgical resection. A paper published in the journal Gastroenterology in 2013 reported the results of an internationalmulticenter study associated with the 5-gene prognostic signature covered by the current agreement. The authors of this study reported that this signature had better predictive accuracy than other gene expression signatures identified to date for patients with liver cancer.
Disease: hepatocellular carcinoma
Details: * On December 2, 2014, IntegraGen announced that it has entered into an agreement with Inserm Transfert and Paris Descartes University providing the company the worldwide licensing rights for two hepatocellular carcinoma (HCC) molecular signatures which have potential clinical utility for monitoring patients with liver cancer. The signatures are comprised of a set of 55 genes that allow the distinction between benign and malignant liver tumors and their different histological subtypes.The expression signatures covered by this agreement are a result of research conducted by Jessica Zucman-Rossi, M.D., Ph.D., Professor of Medical Oncology at the Paris Descartes University, Georges Pompidou European Hospital and Director of INSERM Unit 1162 which focuses on the functional genomics of solid tumors. This research was funded in part by the Tumor Identity Cards Program of the National League Against Cancer, Paris Descartes University, and INSERM, with the latter two being co-owners, along with IntegraGen, of the patents covering these signatures. These two academic laboratories have granted IntegraGen the exclusive worldwide license for the use of these patents.
Financial terms:
Latest news:
